Digital Journal

CMO/CDMO Market Expected to Reach USD 41.75 Billion by 2030: A Deep Dive into Growth Drivers


The Contract Manufacturing Organization (CMO) and Contract Development and Manufacturing Organization (CDMO) market has been experiencing significant growth in recent years, driven by the increasing complexity of pharmaceutical and biotechnology products, as well as the desire of companies to focus on their core competencies while outsourcing manufacturing tasks. According to recent research, the CMO/CDMO market was valued at USD 18.92 Billion in 2022 and is projected to reach USD 41.75 Billion by 2030, with a compound annual growth rate (CAGR) of 10.4% during the forecast period from 2023 to 2030.


Market Analysis:

Several factors are driving the growth of the CMO/CDMO market. The increasing prevalence of chronic diseases, the rise in personalized medicine, and the growing demand for biologics and biosimilars are fueling the need for outsourcing manufacturing activities. Additionally, stringent regulations and the need for cost optimization are encouraging companies to seek external partners with specialized capabilities.

Download Free Sample Report of CMO/CDMO Market @

List of CMO/CDMO Companies Profiled in Report:

  • Piramal Pharma Solutions
  • Samsung Biologics
  • Eurofins Scientific
  • mAbxience
  • Lonza
  • CoreRx
  • Laurus Synthesis
  • KBI Biopharma.
  • Sai Life Sciences
  • Idifarma
  • QuayPharma
  • BDR Pharmaceuticals Internationals Pvt. Ltd.
  • HIKAL Ltd

Key Findings from the Report:

  • By Service: The contract manufacturing segment is expected to dominate the market, driven by the increasing demand for outsourced manufacturing services, particularly for active pharmaceutical ingredients (APIs) and finished dosage forms.
  • By End User: Large pharmaceutical companies are anticipated to capture the largest market share, as they continue to outsource various stages of drug development and manufacturing to optimize costs and operational efficiency.
  • By Region: North America and Europe are expected to lead the CMO/CDMO market, owing to the presence of well-established pharmaceutical and biotechnology industries, as well as favorable regulatory environments.

Regional Analysis:

  • North America (36% market share in 2022): Largest market driven by the presence of major pharmaceutical and biotechnology companies, supportive regulatory environment, and increasing demand for outsourcing services.
  • Europe (29%): Growing prevalence of chronic diseases, increasing investments in drug development, and stringent regulatory requirements are fueling market growth.
  • Asia Pacific (24%): Rapidly expanding market due to the presence of low-cost manufacturing facilities, increasing R&D activities, and rising healthcare expenditure.

Key Developments in the CMO/CDMO Market:

  • In 2022, Catalent acquired Metrics Contract Services, expanding its biologics manufacturing capabilities.
  • Lonza and Moderna collaborated in 2021 to establish a new manufacturing facility for mRNA vaccines and therapeutics.
  • Expansion of service offerings by key players to include specialized services such as cell and gene therapy manufacturing, and highly potent active pharmaceutical ingredient (HPAPI) handling.

Key Takeaways from the CMO/CDMO Market Study:

  • Rising demand for specialized services, such as biologics and advanced therapy medicinal products (ATMPs) manufacturing, is driving market growth.
  • The biologics segment is expected to witness significant growth due to the increasing demand for biologic drugs and the need for specialized manufacturing capabilities.
  • Small and mid-sized pharmaceutical and biotechnology companies are major consumers of CMO/CDMO services, outsourcing manufacturing to reduce costs and focus on core competencies.

Have Any Query? Ask Our Experts @

Emerging Trends and Opportunities:

  • Biologics and Biosimilars: With the rise in biologics and biosimilars in the pharmaceutical industry, CMOs/CDMOs with expertise in bioprocessing and biomanufacturing are in high demand.
  • Advanced Therapies: The growing interest in cell and gene therapies presents a significant opportunity for CMOs/CDMOs with expertise in cell culture, gene editing, and viral vector production.
  • Digitalization: The adoption of digital technologies such as artificial intelligence, machine learning, and advanced analytics is enhancing efficiency, quality, and transparency in manufacturing processes.
  • Sustainability: There is a growing emphasis on sustainability and environmentally friendly manufacturing practices, presenting opportunities for CMOs/CDMOs to differentiate themselves in the market.

Challenges and Considerations:

  • Quality and Compliance: Ensuring compliance with regulatory requirements and maintaining high-quality standards throughout the manufacturing process is critical.
  • Intellectual Property Protection: Protecting intellectual property rights and maintaining confidentiality when outsourcing manufacturing activities is a concern for many companies.
  • Capacity Constraints: The capacity of CMOs/CDMOs to meet the growing demand for manufacturing services may become a limiting factor, leading to potential supply chain disruptions.
  • Pricing Pressures: Intense competition among CMOs/CDMOs and pricing pressures from clients may impact profitability.

Data-driven Recommendations:

To capitalize on the opportunities in the CMO/CDMO market and overcome the challenges, companies can consider the following recommendations:

  • Strategic Partnerships: Form strategic partnerships with CMOs/CDMOs that offer complementary capabilities and expertise to enhance competitiveness and mitigate risks.
  • Invest in Technology: Embrace digital technologies to improve efficiency, quality, and transparency in manufacturing processes, thereby gaining a competitive edge.
  • Focus on Differentiation: Differentiate your offerings by emphasizing factors such as quality, reliability, sustainability, and flexibility to attract and retain clients.
  • Ensure Compliance: Implement robust quality management systems and adhere to regulatory requirements to build trust and credibility with clients and regulatory authorities.
  • Monitor Market Trends: Stay abreast of emerging trends and evolving customer needs to adapt your strategies and offerings accordingly.

Purchase CMO/CDMO Market Report @

About US:

SNS Insider has been a leader in data and analytics globally with its authentic consumer and market insights. The trust of our clients and business partners has always been at the center of who we are as a company. We are a business that leads the industry in innovation, and to support the success of our clients, our highly skilled engineers, consultants, and data scientists have consistently pushed the limits of the industry with innovative methodology and measuring technologies.

We assist our clients to anticipate industrial, economic, and consumer trends to drive disruptive change by fusing global experience with local information from experts throughout the world. We bring context to strategic and tactical data by bridging approaches based on data science and field research, assisting you in addressing your most pressing problems and spotting possibilities.

Contact Us:

Akash Anand – Head of Business Development & Strategy,

[email protected],

Phone: +1-415-230-0044 (US) | +91-7798602273 (IND),


Information contained on this page is provided by an independent third-party content provider. Binary News Network and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact [email protected]


Opioid Use Disorder Market Expected to Reach USD 6.15 Billion by 2030: SNS Insider

Previous article

Leukemia Therapeutics Market Expected to Grow at USD 13491.42 Million by 2030: SNS Insider

Next article

You may also like


Comments are closed.